Drug racing to $1 billion on PBS

Posted 11 March 2025 AM

MSD's monoclonal antibody Keytruda is off to a cracker start for 2025, as the drug solidifies its place at the top of the earnings table.

In January MSD's anti-cancer medicine earned $96.85 million in pre-rebate R\PBS reimbursements, an extra two-thirds above what it earned in December, and 45 per cent above its previous highest earning month, October 2024.

To see the whole article, please login